Comparative Study of Regulatory Requirements for Drug Approval (USFDA vs. EMA vs. INDIA)

Before a new drug can be approved for import or manufacturing, it must be proven safe and effective for humans. Every nation has a regulatory body that examines research data to ensure the medication complies with safety and efficacy standards for public health. The regulatory affairs division of a company plays an essential role in guaranteeing adherence to the laws, regulations, and guidelines established by different regulatory authorities in other countries.[1] This article seeks to examine the different facets of the drug authorization procedure in the USA, Europe, and India. Current limitations in Regulatory Affairs show that countries must adhere to various regulatory criteria for obtaining Marketing Authorization Application (MAA) approval for new medications.[2] The relevant authority reviews the application for drug approval and grants it if satisfied that the drug is safe, effective, and of high quality. Even after a drug receives approval, the government continues to monitor its safety during Phase IV. While the approval processes differ between countries, this study assesses the regulations from the USFDA, EMA, and CDSCO. It also emphasizes the advancements and challenges in the development of cell therapies. In the USA, the FDA regulates drug approvals through a well-defined process that includes Investigational New Drug applications, clinical trials, and NDA submissions. The EMA in the Europe employes centralized, decentralized, mutual recognition, and national procedures to provides in India, the approval of drugs is overseen by the CDSCO. Increasingly aligning with global standards while retaining the flexibility needed to promote domestic pharmaceutical growth.[2].